ppar gamma

Summary

Summary: A nuclear transcription factor. Heterodimerization with RETINOID X RECEPTOR ALPHA is important in regulation of GLUCOSE metabolism and CELL GROWTH PROCESSES. It is a target of THIAZOLIDINEDIONES for control of DIABETES MELLITUS.

Top Publications

  1. pmc Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance
    Justin I Odegaard
    Division of Endocrinology, Metabolism and Gerontology, Department of Medicine, Stanford University School of Medicine, Stanford, California 94305 5103, USA
    Nature 447:1116-20. 2007
  2. ncbi Forming functional fat: a growing understanding of adipocyte differentiation
    Ana G Cristancho
    Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, The Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Nat Rev Mol Cell Biol 12:722-34. 2011
  3. pmc PRDM16 controls a brown fat/skeletal muscle switch
    Patrick Seale
    Dana Farber Cancer Institute and the Department of Cell Biology, Harvard Medical School, 1 Jimmy Fund Way, Boston, Massachusetts 02115, USA
    Nature 454:961-7. 2008
  4. pmc Obesity-associated improvements in metabolic profile through expansion of adipose tissue
    Ja Young Kim
    Department of Cell Biology, Albert Einstein College of Medicine, New York, New York, USA
    J Clin Invest 117:2621-37. 2007
  5. ncbi Fat and beyond: the diverse biology of PPARgamma
    Peter Tontonoz
    Howard Hughes Medical Institute and Department of Pathology and Laboratory Medicine, University of California Los Angeles, CA 90095, USA
    Annu Rev Biochem 77:289-312. 2008
  6. ncbi PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties
    M Amine Bouhlel
    Institut Pasteur de Lille, F 59019 Lille, France INSERM, U545, F 59019 Lille, France
    Cell Metab 6:137-43. 2007
  7. pmc Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes
    Adilson Guilherme
    Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
    Nat Rev Mol Cell Biol 9:367-77. 2008
  8. ncbi The many faces of PPARgamma
    Michael Lehrke
    Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, and The Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Cell 123:993-9. 2005
  9. ncbi Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells
    Christopher K Glass
    Department of Cellular and Molecular Medicine, University of California, San Diego, 9500 Gilman Drive, GPL Room 217A, La Jolla, California 92093 0651, USA
    Nat Rev Immunol 10:365-76. 2010
  10. pmc Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis
    Ronni Nielsen
    Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense M, Denmark
    Genes Dev 22:2953-67. 2008

Detail Information

Publications393 found, 100 shown here

  1. pmc Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance
    Justin I Odegaard
    Division of Endocrinology, Metabolism and Gerontology, Department of Medicine, Stanford University School of Medicine, Stanford, California 94305 5103, USA
    Nature 447:1116-20. 2007
    ....
  2. ncbi Forming functional fat: a growing understanding of adipocyte differentiation
    Ana G Cristancho
    Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, The Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Nat Rev Mol Cell Biol 12:722-34. 2011
    ..Improving our understanding of these mechanisms may allow us to identify therapeutic targets against metabolic diseases that are rapidly becoming epidemic globally...
  3. pmc PRDM16 controls a brown fat/skeletal muscle switch
    Patrick Seale
    Dana Farber Cancer Institute and the Department of Cell Biology, Harvard Medical School, 1 Jimmy Fund Way, Boston, Massachusetts 02115, USA
    Nature 454:961-7. 2008
    ..Taken together, these data indicate that PRDM16 specifies the brown fat lineage from a progenitor that expresses myoblast markers and is not involved in white adipogenesis...
  4. pmc Obesity-associated improvements in metabolic profile through expansion of adipose tissue
    Ja Young Kim
    Department of Cell Biology, Albert Einstein College of Medicine, New York, New York, USA
    J Clin Invest 117:2621-37. 2007
    ..These mice therefore represent what we believe is a novel model of morbid obesity associated with an improved metabolic profile...
  5. ncbi Fat and beyond: the diverse biology of PPARgamma
    Peter Tontonoz
    Howard Hughes Medical Institute and Department of Pathology and Laboratory Medicine, University of California Los Angeles, CA 90095, USA
    Annu Rev Biochem 77:289-312. 2008
    ..Here, we review recent advances in our understanding of the diverse biological actions of PPARgamma with an eye toward the expanding therapeutic potential of PPARgamma agonist drugs...
  6. ncbi PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties
    M Amine Bouhlel
    Institut Pasteur de Lille, F 59019 Lille, France INSERM, U545, F 59019 Lille, France
    Cell Metab 6:137-43. 2007
    ..These data demonstrate that PPARgamma activation skews human monocytes toward an anti-inflammatory M2 phenotype...
  7. pmc Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes
    Adilson Guilherme
    Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
    Nat Rev Mol Cell Biol 9:367-77. 2008
    ....
  8. ncbi The many faces of PPARgamma
    Michael Lehrke
    Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, and The Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Cell 123:993-9. 2005
    ....
  9. ncbi Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells
    Christopher K Glass
    Department of Cellular and Molecular Medicine, University of California, San Diego, 9500 Gilman Drive, GPL Room 217A, La Jolla, California 92093 0651, USA
    Nat Rev Immunol 10:365-76. 2010
    ..These nuclear receptor-dependent transrepression pathways are proposed to have roles in controlling the initiation, magnitude and duration of pro-inflammatory gene expression and are amenable to pharmacological manipulation...
  10. pmc Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis
    Ronni Nielsen
    Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense M, Denmark
    Genes Dev 22:2953-67. 2008
    ....
  11. pmc Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5
    Jang Hyun Choi
    Department of Cancer Biology and Division of Metabolism and Chronic Disease, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 466:451-6. 2010
    ....
  12. pmc Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones
    Paul A Dutchak
    Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9041, USA
    Cell 148:556-67. 2012
    ..Adding back FGF21 prevents sumoylation and restores PPARγ activity. Collectively, these results reveal FGF21 as a key mediator of the physiologic and pharmacologic actions of PPARγ...
  13. ncbi Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program
    S Muruganandan
    Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, B3H 1X5, Canada
    Cell Mol Life Sci 66:236-53. 2009
    ..of adipocyte and osteoblast differentiation including peroxisome proliferator-activated receptor-gamma (PPAR gamma) and runt-related transcription factor 2 (Runx2)...
  14. pmc Transcriptional control of preadipocyte determination by Zfp423
    Rana K Gupta
    Department of Cancer Biology and Division of Metabolism and Chronic Disease, Dana Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 464:619-23. 2010
    ..This study identifies Zfp423 as a transcriptional regulator of preadipocyte determination...
  15. ncbi TAZ, a transcriptional modulator of mesenchymal stem cell differentiation
    Jeong Ho Hong
    Center for Cancer Research, Department of Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, E18 580, Cambridge, MA 02139, USA
    Science 309:1074-8. 2005
    ..These results indicate that TAZ functions as a molecular rheostat that modulates MSC differentiation...
  16. pmc Modulation of PPAR activity via phosphorylation
    Katherine A Burns
    Department of Veterinary and Biomedical Sciences and Center for Molecular Toxicology and Carcinogenesis, Penn State University, University Park, PA 16802, USA
    Biochim Biophys Acta 1771:952-60. 2007
    ..The review will summarize the known PPAR kinases that directly act on these receptors, the sites affected and the result of this modification on receptor activity...
  17. pmc Comparative epigenomic analysis of murine and human adipogenesis
    Tarjei S Mikkelsen
    Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA
    Cell 143:156-69. 2010
    ..We also utilize the close relationship between open chromatin marks and transcription factor motifs to identify and validate PLZF and SRF as regulators of adipogenesis...
  18. ncbi Mechanisms of disease: is osteoporosis the obesity of bone?
    Clifford J Rosen
    The Jackson Laboratory in Bar Harbor, ME 04401, USA
    Nat Clin Pract Rheumatol 2:35-43. 2006
    ....
  19. pmc Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation
    Jang Hyun Choi
    Department of Cancer Biology and Division of Metabolism and Chronic Disease, Dana Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 477:477-81. 2011
    ..Unlike TZDs, SR1664 also does not interfere with bone formation in culture. These data illustrate that new classes of antidiabetes drugs can be developed by specifically targeting the Cdk5-mediated phosphorylation of PPARγ...
  20. pmc Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA
    Vikas Chandra
    Department of Pharmacology, and Center for Molecular Design, University of Virginia Health System, 1300 Jefferson Park Avenue, Charlottesville, Virginia 22908 0735, USA
    Nature 456:350-6. 2008
    ..The PPAR-gamma LBD cooperates with both DNA-binding domains (DBDs) to enhance response-element binding. The A/B segments are highly dynamic, lacking folded substructures despite their gene-activation properties...
  21. pmc Amorfrutins are potent antidiabetic dietary natural products
    Christopher Weidner
    Otto Warburg Laboratory, Max Planck Institute for Molecular Genetics, Ihnestrasse 63 73, 14195 Berlin, Germany
    Proc Natl Acad Sci U S A 109:7257-62. 2012
    ..These results show that selective PPARγ-activation by diet-derived ligands may constitute a promising approach to combat metabolic disease...
  22. pmc Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma
    Serena Ghisletti
    Department of Cellular and Molecular Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Mol Cell 25:57-70. 2007
    ..These studies define parallel but functionally distinct pathways that are utilized by PPARgamma and LXRs to differentially regulate complex programs of gene expression that control immunity and homeostasis...
  23. ncbi Review: Peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism
    Arya M Sharma
    Canada Research Chair for Cardiovascular Obesity Research and Management, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, Canada L8L 2X2
    J Clin Endocrinol Metab 92:386-95. 2007
    ..e. adipocytes display morphological differences alongside aberrant endocrine and metabolic function and low-grade inflammation)...
  24. pmc PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale
    Martina I Lefterova
    Institute for Diabetes, Obesity, and Metabolism, and Division of Endocrinology, Diabetes, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Genes Dev 22:2941-52. 2008
    ..Thus, PPARgamma and C/EBP factors cooperatively orchestrate adipocyte biology by adjacent binding on an unanticipated scale...
  25. pmc Perinatal exposure to bisphenol a alters early adipogenesis in the rat
    Emmanuel Somm
    Faculty of Medicine, University of Geneva, Geneva, Switzerland
    Environ Health Perspect 117:1549-55. 2009
    ..The causes of the current obesity pandemic have not been fully elucidated. Implication of environmental endocrine disruptors such as bisphenol A (BPA) on adipose tissue development has been poorly investigated...
  26. ncbi Curcumin ameliorates renal failure in 5/6 nephrectomized rats: role of inflammation
    S S Ghosh
    Department of Internal Medicine Nephrology, Sanger Hall, Rm 8 059, Virginia Commonwealth Univ, 1101 E Marshall St, Richmond, VA 23298, USA
    Am J Physiol Renal Physiol 296:F1146-57. 2009
    ....
  27. pmc PPARγ: a circadian transcription factor in adipogenesis and osteogenesis
    Masanobu Kawai
    Center for Clinical and Translational Research, Maine Medical Center Research Institute, 81 Research Drive, Scarborough, ME 04074 7205, USA
    Nat Rev Endocrinol 6:629-36. 2010
    ....
  28. pmc PPARγ agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein
    Haruya Ohno
    UCSF Diabetes Center and Department of Cell and Tissue Biology, University of California, San Francisco, 35 Medical Center Way, San Francisco, CA 94143 0669, USA
    Cell Metab 15:395-404. 2012
    ..Identifying compounds that stabilize PRDM16 protein may represent a plausible therapeutic pathway for the treatment of obesity and diabetes...
  29. ncbi Role of peroxisome proliferator-activated receptor-γ in atherosclerosis: an update
    Nanping Wang
    Key Laboratory of Molecular Cardiovascular Sciences at Peking University, Beijing, 100191, China
    Circ J 75:528-35. 2011
    ..Therefore, this review will focus on the recent advances regarding the cardiovascular functions of PPARγ and its recognized effects on major cardiovascular diseases, in particular, atherosclerosis and associated processes...
  30. pmc Oxidative stress modulates PPAR gamma in vascular endothelial cells
    Carmelo Blanquicett
    Department of Medicine, Emory University, and Atlanta VA Medical Centers, Atlanta, GA 30033, USA
    Free Radic Biol Med 48:1618-25. 2010
    The peroxisome proliferator-activated receptor gamma (PPAR gamma) plays an important role in vascular regulation. However, the impact of oxidative stress on PPAR gamma expression and activity has not been clearly defined...
  31. ncbi Anti-inflammatory and antidiabetic roles of PPARgamma
    Gabriel Pascual
    Biomedical Sciences Graduate Program, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA
    Novartis Found Symp 286:183-96; discussion 196-203. 2007
    ....
  32. ncbi Differentiation of human circulating fibrocytes as mediated by transforming growth factor-beta and peroxisome proliferator-activated receptor gamma
    Kurt M Hong
    Center for Human Nutrition and the Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California 90024, USA
    J Biol Chem 282:22910-20. 2007
    ....
  33. pmc PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism
    Gema Medina-Gomez
    Department of Clinical Biochemistry, Histopathology, University of Cambridge Addenbrooke s Hospital, Cambridge, United Kingdom
    PLoS Genet 3:e64. 2007
    ....
  34. ncbi Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice
    Susanne Neschen
    Howard Hughes Medical Institute, Yale Medical School, P O Box 9812, New Haven, CT 06536 8012, USA
    Diabetes 55:924-8. 2006
    ..These data suggest that fish oil is a naturally occurring potent regulator of adiponectin secretion in vivo and that it does so through a PPARgamma-dependent and PPARalpha-independent manner in epididymal fat...
  35. ncbi PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes
    Susan E Schadinger
    Dept of Biochemistry, Boston Univ School of Medicine, 715 Albany St, Boston, MA 02118, USA
    Am J Physiol Endocrinol Metab 288:E1195-205. 2005
    ..Taken together, these observations propose a role for PPARgamma2 as an inducer of steatosis in hepatocytes and suggest that this phenomenon occurs through an induction of pathways regulating de novo lipid synthesis...
  36. ncbi Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice
    Michael T Heneka
    Department of Neurology, University of Bonn, Bonn, Germany
    Brain 128:1442-53. 2005
    ..These findings demonstrate that anti-inflammatory drugs can act rapidly to inhibit inflammatory responses in the brain and negatively modulate amyloidogenesis...
  37. pmc Cell-specific determinants of peroxisome proliferator-activated receptor gamma function in adipocytes and macrophages
    Martina I Lefterova
    University of Pennsylvania School of Medicine, 700 CRB, 415 Curie Blvd, Philadelphia, PA 19104 6149, USA
    Mol Cell Biol 30:2078-89. 2010
    ..Our data support the existence of an epigenomic hierarchy in which PPARgamma binding to cell-specific sites not marked by repressive marks opens chromatin and leads to local activation marks, including histone acetylation...
  38. ncbi Preadipocytes mediate lipopolysaccharide-induced inflammation and insulin resistance in primary cultures of newly differentiated human adipocytes
    Soonkyu Chung
    Department of Nutrition, 318 Stone Building, P O Box 26170, University of North Carolina at Greensboro, Greensboro, North Carolina 27402 6170, USA
    Endocrinology 147:5340-51. 2006
    ....
  39. pmc Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model
    Rachel E Nisbet
    Department of Medicine, Atlanta Veterans Affairs and Emory University Medical Centers, Atlanta, Georgia 30033, USA
    Am J Respir Cell Mol Biol 42:482-90. 2010
    ....
  40. ncbi miR-27a is a negative regulator of adipocyte differentiation via suppressing PPARgamma expression
    Sang Yun Kim
    Institute of Molecular Biology and Genetics, Seoul National University, Kwanak gu, Seoul, Republic of Korea
    Biochem Biophys Res Commun 392:323-8. 2010
    ..Together, these results suggest that miR-27a would suppress adipocyte differentiation through targeting PPARgamma and thereby down-regulation of miR-27a might be associated with adipose tissue dysregulation in obesity...
  41. ncbi Arginase I induction by modified lipoproteins in macrophages: a peroxisome proliferator-activated receptor-gamma/delta-mediated effect that links lipid metabolism and immunity
    Alejandro Gallardo-Soler
    Departamento de Bioquimica y Biologia Molecular y Genetica, Universidad de Extremadura Avenida de la Universidad s n, 10071 Caceres, Spain
    Mol Endocrinol 22:1394-402. 2008
    ..Collectively, our results strongly suggest that ArgI is a key marker of the alternative program triggered by PPAR in macrophages...
  42. ncbi PPARgamma in adipocyte differentiation and metabolism--novel insights from genome-wide studies
    Rasmus Siersbaek
    Department of Biochemistry and Molecular Biology, University of Southern Denmark, 5230 Odense, Denmark
    FEBS Lett 584:3242-9. 2010
    ..As more genome-wide data emerge in the future, this crosstalk will likely be found to include several other adipogenic transcription factors...
  43. ncbi Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 294:2581-6. 2005
    ....
  44. pmc Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway
    Hui H Zhang
    Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, MA, USA
    PLoS ONE 4:e6189. 2009
    ....
  45. ncbi Identification of bioactive compounds from flowers of black elder (Sambucus nigra L.) that activate the human peroxisome proliferator-activated receptor (PPAR) gamma
    Kathrine B Christensen
    Department of Food Science, Aarhus University, Kirstinebjergvej 10, Aarslev, Denmark
    Phytother Res 24:S129-32. 2010
    ..These findings suggest that flavonoid glycosides cannot activate PPARgamma, whereas some of their aglycones are potential agonists of PPARgamma...
  46. ncbi Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist
    R Agrawal
    Department of Chemistry, Shrimant Madhavrao Scindia, Government Model Science College, Jhansi Road, Gwalior, Madhya Pradesh, India
    Mini Rev Med Chem 12:87-97. 2012
    ..Unlike other marketed PPAR gamma agonists, Balaglitazone shows less fluid retention, less heart enlargement and no reduction of bone formation ..
  47. pmc N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo
    Kavita Bhalla
    Marlene and Stewart Greenebaum Cancer Center, Harvard University Medical School, Boston, Massachusetts 02215, USA
    J Biol Chem 286:41626-35. 2011
    ..In conclusion, we describe a new approach for the identification of differential SPPARMs and have identified AFC as a novel class of PPARγ ligand with both full and partial agonist activity in vitro and in vivo...
  48. pmc PER2 controls lipid metabolism by direct regulation of PPARγ
    Benedetto Grimaldi
    Department of Pharmacology, University of California, Irvine, 92697, USA
    Cell Metab 12:509-20. 2010
    ..Our findings support a scenario in which PER2 controls the proadipogenic activity of PPARγ by operating as its natural modulator, thereby revealing potential avenues of pharmacological and therapeutic intervention...
  49. pmc Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone
    Leanne Wilson-Fritch
    Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, 01601, USA
    J Clin Invest 114:1281-9. 2004
    ....
  50. pmc PPAR gamma, bioactive lipids, and cancer progression
    Gregory T Robbins
    Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine
    Front Biosci (Landmark Ed) 17:1816-34. 2012
    ..We predict that indicators of PPARgamma activity may also serve as predictive markers for tailoring treatments...
  51. pmc FOXO1 transrepresses peroxisome proliferator-activated receptor gamma transactivation, coordinating an insulin-induced feed-forward response in adipocytes
    WuQiang Fan
    Division of Endocrinology Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California 92093, USA
    J Biol Chem 284:12188-97. 2009
    ....
  52. pmc PPARgamma as a new therapeutic target in inflammatory bowel diseases
    L Dubuquoy
    INSERM U795 ex E114, Clinique des maladies de l appareil digestif et de la nutrition, Hôpital Swynghedauw, Rue A Verhaeghe, F 59037 Lille Cedex, France
    Gut 55:1341-9. 2006
    ..The aims of this review are to discuss the potential roles of PPARgamma in the physiopathology of IBD, as well as the emerging therapeutic strategies targeting this receptor...
  53. ncbi Cyclic phosphatidic acid decreases proliferation and survival of colon cancer cells by inhibiting peroxisome proliferator-activated receptor γ
    Tamotsu Tsukahara
    Department of Integrative Physiology and Bio System Control, Shinshu University School of Medicine, 3 1 1 Asahi, Matsumoto 390 8621, Nagano, Japan
    Prostaglandins Other Lipid Mediat 93:126-33. 2010
    ..Our results identify PPARγ as a molecular mediator of cPA activity in HT-29 cells, and suggest that cPA and the PPARγ pathway might be therapeutic targets in the treatment of colon cancer...
  54. pmc PPAR-γ ligands repress TGFβ-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis
    Ajit A Kulkarni
    The Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America
    PLoS ONE 6:e15909. 2011
    ..Further studies of PPAR-γ ligands and small electrophilic molecules may lead to a new generation of anti-fibrotic therapeutics...
  55. pmc C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists
    Cecile Vernochet
    Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Mol Cell Biol 29:4714-28. 2009
    ..Developing strategies to enhance the brown phenotype in white adipocytes while reducing secretion of stress-related cytokines from visceral WAT is a means to combat obesity-associated disorders...
  56. ncbi 12/15-Lipoxygenase inhibitor baicalein suppresses PPAR gamma expression and nuclear translocation induced by cerebral ischemia/reperfusion
    Yan Wei Xu
    Tianjin Neurology Institute, Tianjin Medical University General Hospital, 154 Anshan Road Heping District, Tianjin 300052, China
    Brain Res 1307:149-57. 2010
    ..evidences have demonstrated the beneficial actions of peroxisome proliferator-activated receptor gamma (PPAR gamma) in a variety of animal stroke models...
  57. ncbi Krüppel-like transcription factor KLF5 is a key regulator of adipocyte differentiation
    Yumiko Oishi
    Department of Cardiovascular Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo, Tokyo 113 8655, Japan
    Cell Metab 1:27-39. 2005
    ..KLF5, in turn, acts in concert with C/EBPbeta/delta to activate the PPARgamma2 promoter. This study establishes KLF5 as a key component of the transcription factor network controlling adipocyte differentiation...
  58. ncbi Anti-apoptotic actions of PPAR-gamma against ischemic stroke
    Wen Hsuan Fong
    Neuroscience Division, Institute of Biomedical Sciences, Academia Sinica, Rm 404, Taipei, Taiwan, Republic of China
    Mol Neurobiol 41:180-6. 2010
    ..This review further supports the notion that PPAR-gamma may serve as a potential therapeutic target for treating ischemic stroke...
  59. pmc The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B
    L P Quinn
    Neurology and Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, UK
    Br J Pharmacol 154:226-33. 2008
    ....
  60. pmc STAT6 transcription factor is a facilitator of the nuclear receptor PPARγ-regulated gene expression in macrophages and dendritic cells
    Attila Szanto
    Department of Biochemistry and Molecular Biology, University of Debrecen, Medical and Health Science Center, Research Center for Molecular Medicine, Egyetem ter 1 Debrecen, H 4010, Hungary
    Immunity 33:699-712. 2010
    ..This interaction, underpinning cell type-specific responses, represents a unique way of controlling nuclear receptor signaling by inflammatory molecules in immune cells...
  61. ncbi Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination
    Atsushi Tsuchida
    Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Diabetes 54:3358-70. 2005
    ....
  62. pmc Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice
    Eleni Maniati
    Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
    J Clin Invest 121:4685-99. 2011
    ..These findings reveal what we believe to be a novel interaction between oncogenic inflammation and a major cell fate pathway and show how these pathways can cooperate to promote cancer progression...
  63. ncbi Macrophage paraoxonase 2 (PON2) expression is up-regulated by pomegranate juice phenolic anti-oxidants via PPAR gamma and AP-1 pathway activation
    Maayan Shiner
    Lipid Research Laboratory, Technion Faculty of Medicine, The Rappaport Family Institute for Research in the Medical Sciences and Rambam Medical Center, Haifa 31096, Israel
    Atherosclerosis 195:313-21. 2007
    ..PJ polyphenol-induced up-regulation of PON2 was inhibited by 40% upon using the PPAR gamma inhibitor GW9662 (50 microM)...
  64. ncbi Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats
    Yi Zhao
    Institute of Pharmacology, University Hospital of Schleswig Holstein, Campus Kiel Hospitalstrasse 4 24105 Kiel, Germany
    FASEB J 20:1162-75. 2006
    ..Our data provide evidence that activation of neuronal PPARgamma considerably contributes to neuroprotection by prevention of COX-2 up-regulation in vitro and in peri-infarct brain areas...
  65. pmc De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis
    Mohamed Sabry Hamza
    Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore
    PLoS ONE 4:e4907. 2009
    ..In order to obtain a genome-wide view of PPARgamma binding sites, we applied the pair end-tagging technology (ChIP-PET) to map PPARgamma binding sites in 3T3-L1 preadipocyte cells...
  66. pmc Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones
    Min Lu
    Department of Medicine, University of California San Diego UCSD, San Diego, California, USA
    Nat Med 17:618-22. 2011
    ..Neuronal PPAR-γ signaling is also required for the hepatic insulin sensitizing effects of TZDs...
  67. pmc PPAR gamma is highly expressed in F4/80(hi) adipose tissue macrophages and dampens adipose-tissue inflammation
    Josep Bassaganya-Riera
    Virginia Bioinformatics Institute, Virginia Polytechnic Institute and State University, Blacksburg, 24061, United States
    Cell Immunol 258:138-46. 2009
    ..Hence, we hypothesized that F4/80(hi) and F4/80(lo) ATM differentially express PPAR gamma. This study phenotypically and functionally characterizes F4/80(hi) and F4/80(lo) ATM subsets during obesity...
  68. ncbi Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis
    Karen Fuenzalida
    Centro de Regulación Celular y Patologia Joaquín V Luco and Millennium Institute for Fundamental and Applied Biology, Department of Cellular and Molecular Biology, Facultad de Ciencias Biologicas, Pontificia Universidad Catolica de Chile, Santiago, Chile
    J Biol Chem 282:37006-15. 2007
    ..Altogether, these data suggest that PPARgamma supports survival in neurons in part through a mechanism involving increased expression of Bcl-2...
  69. ncbi Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis
    Raquel Hontecillas
    Laboratory of Nutritional Immunology and Molecular Nutrition, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA
    J Immunol 178:2940-9. 2007
    ..In conclusion, our data suggest that endogenous PPAR-gamma activation represents a Treg intrinsic mechanism of down-regulation of effector CD4+ T cell function and prevention of colitis...
  70. pmc The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity
    Luisa Klotz
    Institutes of Molecular Medicine and Experimental Immunology, Department of Neurology, University of Bonn, Bonn 53105, Germany
    J Exp Med 206:2079-89. 2009
    ..We identify the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR gamma) as a key negative regulator of human and mouse Th17 differentiation...
  71. ncbi Rosiglitazone induces mitochondrial biogenesis in mouse brain
    Jay C Strum
    Department of Quantitative Expression, Division of Genetics Research, GlaxoSmithKline, Research Triangle Park, NC 27278, USA
    J Alzheimers Dis 11:45-51. 2007
    ....
  72. pmc An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension
    Georg Hansmann
    Department of Pediatrics, Stanford University School of Medicine, Stanford, California 94305 5162, USA
    J Clin Invest 118:1846-57. 2008
    ..Thus, PPARgamma-mediated events could protect against PAH, and PPARgamma agonists may reverse PAH in patients with or without BMP-RII dysfunction...
  73. ncbi Transcriptional and translational regulation of BACE1 expression--implications for Alzheimer's disease
    Steffen Rossner
    Paul Flechsig Institute for Brain Research, Department of Neurochemistry, University of Leipzig, Jahnallee 59, 04109 Leipzig, Germany
    Prog Neurobiol 79:95-111. 2006
    ....
  74. ncbi The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial
    Andrew Grey
    Department of Medicine, University of Auckland, and LabPlus, Auckland City Hospital, New Zealand
    J Clin Endocrinol Metab 92:1305-10. 2007
    ..Human data on the skeletal effects of thiazolidinediones are currently available only from observational studies...
  75. ncbi PPARgamma in endothelial cells influences high fat diet-induced hypertension
    Christopher J Nicol
    Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Hypertens 18:549-56. 2005
    ..However, the mechanism and site of this effect remains unknown, confounded by PPARgamma expression in many cell types, including endothelial cells (ECs)...
  76. pmc Peroxisome proliferator-activated receptor (PPAR)α and -γ regulate IFNγ and IL-17A production by human T cells in a sex-specific way
    Monan Angela Zhang
    Department of Immunology, University of Toronto, Toronto, ON, Canada M5S 1A8
    Proc Natl Acad Sci U S A 109:9505-10. 2012
    ..Together, our observations indicate that human T cells exhibit a sex difference in the production of IFNγ and IL-17A that may be driven by expressions of PPARα and PPARγ...
  77. ncbi The PPARgamma antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and -independent mechanisms
    Yekaterina Y Zaytseva
    University of Kentucky College of Medicine, Department of Molecular and Biomedical Pharmacology and the Markey Cancer Center, 800 Rose St, Room MS305, Lexington, KY 40536 0298, USA
    Anticancer Res 31:813-23. 2011
    ..This study examines whether selective antagonism of PPARγ with T0070907 is a potential strategy for breast cancer therapy...
  78. pmc Inhibition of PPARγ in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis
    Lingyan Wu
    Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202 5188, USA
    Blood 119:115-26. 2012
    ..These studies suggest that anti-inflammatory PPARγ in myeloid-lineage cells plays a key role in controlling pro-inflammatory cytokine synthesis, MDSC expansion, immunosuppression, and the development of cancer...
  79. ncbi Rosiglitazone and PPAR-gamma overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins
    Jui Sheng Wu
    Graduate Institute of Life Sciences, National Defense Medical Center Taipei, Taiwan
    J Cell Physiol 220:58-71. 2009
    ..These results indicate that ligand-activated PPAR-gamma protects N2-A cells against H-R damage by enhancing Bcl-2/Bcl-xl and maintaining p-Bad via preservation of p-Akt...
  80. pmc Molecular determinants of magnolol targeting both RXRα and PPARγ
    Haitao Zhang
    State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
    PLoS ONE 6:e28253. 2011
    ....
  81. ncbi Hedgehog signaling plays a conserved role in inhibiting fat formation
    Jae Myoung Suh
    Center for Developmental Biology, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, NB5 118, Dallas, Texas 75390, USA
    Cell Metab 3:25-34. 2006
    ....
  82. pmc Regulation of nuclear translocation of HDAC3 by IkappaBalpha is required for tumor necrosis factor inhibition of peroxisome proliferator-activated receptor gamma function
    Zhanguo Gao
    Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, 70808, USA
    J Biol Chem 281:4540-7. 2006
    ..Rather, these results suggest that IkappaBalpha-dependent nuclear translocation of HDAC3 is responsible for PPARgamma inhibition by TNF-alpha...
  83. ncbi Mode of peroxisome proliferator-activated receptor γ activation by luteolin
    Ana C Puhl
    Instituto de Fisica de Sao Carlos, Universidade de Sao Paulo, Sao Carlos, SP, Brazil
    Mol Pharmacol 81:788-99. 2012
    ..We propose that activities of luteolin are related to its singular binding mode, that anti-inflammatory activity does not require H12 stabilization, and that our structure can be useful in developing safe selective PPARγ modulators...
  84. pmc Modeling the role of peroxisome proliferator-activated receptor γ and microRNA-146 in mucosal immune responses to Clostridium difficile
    Monica Viladomiu
    Nutritional Immunology and Molecular Medicine Laboratory, Virginia Bioinformatics Institute, Virginia Tech, Blacksburg, VA, USA
    PLoS ONE 7:e47525. 2012
    ..In conclusion, our data indicates that miRNA-146b and PPARγ activation may be implicated in the regulation of Th17 responses and colitis in C. difficile-infected mice...
  85. ncbi Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock
    Maha Abdelrahman
    Centre for Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, Charterhouse Square, London, EC1M 6BQ, UK
    Cardiovasc Res 65:772-81. 2005
    ..This review discusses the anti-inflammatory signalling pathways activated by PPAR-gamma, as well as the potential therapeutic effects of PPAR-gamma agonists in animal models of ischemia/reperfusion, inflammation and shock...
  86. ncbi Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis
    Ichiro Takada
    Institute of Molecular and Cellular Biosciences, University of Tokyo, Tokyo, Japan
    Nat Rev Rheumatol 5:442-7. 2009
    ..This article summarizes Wnt and PPARgamma signaling in MSCs and the crosstalk between these pathways, and speculates on future clinical application of this knowledge as the basis of novel approaches for regeneration therapy...
  87. ncbi Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro
    Jun Yu
    Institute of Digestive Disease and Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, Hong Kong, China
    Hepatology 51:2008-19. 2010
    ..Moreover, PPARgamma directly induced a putative tumor suppressor gene, growth differentiation factor-15...
  88. pmc Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients
    Limei Liu
    Department of Endocrinology and Metabolism, Shanghai JiaoTong University Affiliated Sixth People s Hospital, Shanghai Diabetes Institute, Shanghai, China
    Diabetes Care 33:144-9. 2010
    ..To determine whether the Pro12Ala polymorphism, alone or in combination with smoking, contributes to the development of diabetic nephropathy, a case-control study was performed in 760 Chinese patients with type 2 diabetes...
  89. ncbi Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo
    Jun Yu
    Storr Liver Unit, Westmead Millennium Institute, University of Sydney, Westmead Hospital, Westmead, NSW 2145, Australia
    Hepatology 43:134-43. 2006
    ..PPARgamma therefore represents a putative molecular target for chemopreventive therapy or inhibition of liver cancer growth...
  90. ncbi Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes
    Robert E Ratner
    MedStar Research Institute, Hyattsville, MD 20783, USA
    Diab Vasc Dis Res 4:214-21. 2007
    ..The clinical development of tesaglitazar is no longer continuing; its effects on the glucose and lipid abnormalities of type 2 diabetes suggest that the concept of dual PPARalpha/gamma agonism is worthy of further investigation...
  91. pmc Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease
    Rodrigo A Quintanilla
    Department of Anesthesiology, University of Rochester, University Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    J Biol Chem 283:25628-37. 2008
    ....
  92. pmc Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gamma
    Nanang Fakhrudin
    University of Vienna, Department of Pharmacognosy, Vienna, Austria
    Mol Pharmacol 77:559-66. 2010
    Peroxisome proliferator-activated receptor gamma (PPAR gamma) agonists are used for the treatment of type 2 diabetes and metabolic syndrome...
  93. pmc Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia
    Xiurong Zhao
    Stroke Program, Department of Neurology, University of Texas, Houston, Medical School, Houston, Texas 77030, USA
    J Neurosci 29:6186-95. 2009
    ..Therefore, we conclude that PPARgamma in neurons play an essential protective function and that PPARgamma agonists may have utility in neuronal self-defense, in addition to their well established anti-inflammatory effect...
  94. pmc The environmental obesogen tributyltin chloride acts via peroxisome proliferator activated receptor gamma to induce adipogenesis in murine 3T3-L1 preadipocytes
    Xia Li
    Department of Developmental and Cell Biology, University of California, Irvine, CA 92697 2300, United States
    J Steroid Biochem Mol Biol 127:9-15. 2011
    ..Our results are broadly applicable to the study of obesogen action and indicate that ligand stability is an important consideration in the design and interpretation of adipogenesis assays...
  95. pmc A role for central nervous system PPAR-γ in the regulation of energy balance
    Karen K Ryan
    Department of Internal Medicine, Division of Endocrinology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    Nat Med 17:623-6. 2011
    ..These findings have implications for the widespread clinical use of TZD drugs and for understanding the etiology of diet-induced obesity...
  96. ncbi PARP-1 suppresses adiponectin expression through poly(ADP-ribosyl)ation of PPAR gamma in cardiac fibroblasts
    Dan Huang
    Department of Cardiology, Institute of Cardiovascular Disease, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, People s Republic of China
    Cardiovasc Res 81:98-107. 2009
    ..Our aim was to explore the mechanism underlying the transcriptional regulation of adiponectin and its receptors (AdipoR) in cultured rat cardiac fibroblasts...
  97. ncbi Increased maternal nutrition stimulates peroxisome proliferator activated receptor-gamma, adiponectin, and leptin messenger ribonucleic acid expression in adipose tissue before birth
    B S Muhlhausler
    Sansom Research Institute, University of South Australia, Adelaide 5000, South Australia, Australia
    Endocrinology 148:878-85. 2007
    ....
  98. ncbi Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial
    Andrea K Boggild
    Tropical Disease Unit, Toronto General Hospital of the University Health Network, Toronto, Ontario, Canada
    Clin Infect Dis 49:841-9. 2009
    ..We hypothesized that peroxisome proliferator-activated receptor gamma agonists (eg, rosiglitazone) would modulate the host's innate immune response to malaria and improve outcome...
  99. ncbi Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
    John A Dormandy
    Department of Clinical Vascular Research, Ingelby House, St Georges Hospital, Blackshaw Road, London SW17 0QT, UK
    Lancet 366:1279-89. 2005
    ..There is indirect evidence that agonists of peroxisome proliferator-activated receptor gamma (PPAR gamma) could reduce macrovascular complications...
  100. pmc Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids
    Anannya Banga
    The Central Arkansas Veterans Healthcare System, Little Rock, AR 72205, USA
    Am J Physiol Endocrinol Metab 296:E480-9. 2009
    ....
  101. ncbi Organotin compounds promote adipocyte differentiation as agonists of the peroxisome proliferator-activated receptor gamma/retinoid X receptor pathway
    Tomohiko Kanayama
    Department of Environmental Biochemistry, Graduate School of Pharmaceutical Sciences, Osaka University, 1 6 Yamada oka, Suita, Osaka 565 0871, Japan
    Mol Pharmacol 67:766-74. 2005
    ..We found that organotin compounds stimulated differentiation of 3T3-L1 cells as well as expression of adipocyte marker genes...

Research Grants76

  1. Mitochondrial Protection Within Chronically Ischemic Myocardium
    Edward O McFalls; Fiscal Year: 2010
    ..Using this model, we propose that a class of drugs used in diabetic patients that has been associated with heart failure exacerbations, alters the mitochondrial energy production in a similar way. ..
  2. The function(s) and regulation of PPARs in the ovary
    Carolyn Komar; Fiscal Year: 2003
    ..b>PPAR gamma has been shown to play a role in angiogenesis, inflammation, cell differentiation, and steroidogenesis...
  3. Effects of Evoked Resistance Training and Testosterone after Spinal Cord Injury
    Ashraf Gorgey; Fiscal Year: 2012
    ..The completion of the proposed experiment will allow the candidate to compete as an independent research investigator. ..
  4. Effect of PPARy Ligands on Alcohol-Induced Alveolar Macrophage Oxidative Stress
    Samantha M Yeligar; Fiscal Year: 2013
    ..Thus, this K99/R00 application provides an excellent opportunity to advance the career of a talented and promising investigator. ..
  5. Mechanisms and Consequences of Reduced PPAR gamma in Pulmonary Hypertension
    C Michael Hart; Fiscal Year: 2013
    ..The results of this proposal can thereby define novel and effective therapeutic strategies to regulate programs of gene expression involved in PH pathogenesis. ..
  6. Hepatic Steatosis and ER Stress-Inducible Transcription Factor CREBH
    Kezhong Zhang; Fiscal Year: 2013
    ..Understanding the stress-induced molecular mechanisms in hepatic lipid accumulation and its associated pathogenesis is a key prerequisite for the development of new diagnostics and therapeutics targeting NAFLD. ..
  7. Molecular Mechanism of Acrolein-Induced Vascular Toxicity: Role of PPAR gamma and
    Zivar Yousefipour; Fiscal Year: 2013
    ....
  8. Synergistic Roles of Adiponectin & PPARgamma in Beta-Cell Survival/Proliferation
    William L Holland; Fiscal Year: 2010
    ..which improves insulin sensitivity through activation of peroxisome proliferator-activated receptor-gamma (PPAR gamma), a critical transcriptional mediator of adipocyte differentiation...
  9. Inflammation and Immunosuppression in Lung Cancer
    Cong Yan; Fiscal Year: 2013
    ..Accomplishment of the proposed studies will elucidate the molecular mechanism by which the LAL/hormonal ligands/PPAR? axis controls anti-tumor adaptive immunity and pave the way for novel immunotherapy of lung cancer. ..
  10. Dysfunctional PGC-1alpha expression in skeletal muscle during diabetes
    S Russ Price; Fiscal Year: 2013
    ..Use of Cn inhibitors could have a negative impact on both types of patients. Lastly, our results could be broadly applicable to Veterans suffering from many types of debilitating diseases associated with atrophy. ..
  11. Harness Germinal Matrix Hemorrhage
    John H Zhang; Fiscal Year: 2013
    ..The long-term goals of this proposal are to provide non-invasive therapeutic approaches for GMH patients. ..
  12. The Role of PPAR Gamma in Fat-Resident Regulatory T Cells and Glucose Homeostasis
    SAGAR PRADEEP BAPAT; Fiscal Year: 2013
    ..Taken together, these studies will systematically characterize the role of PPAR! in fTregs and illuminate the role of fTregs in the pathogenesis of obesity-related type-2 diabetes. ..
  13. PPAR gamma Agonists for Lung Cancer Chemoprevention
    Robert Keith; Fiscal Year: 2013
    ..Our results will lead to a better understanding of the early stages of lung cancer and may lead to future human chemoprevention trials. ..
  14. Effect of constitutive Type 2 NF-kB on adipogenesis
    LOTUS KYI LOO; Fiscal Year: 2010
    ..We have found that both LBW242 and SM can inhibit PPAR gamma (master regulator of adipogenesis), C/EBPo and downstream adipocytes specific genes...
  15. A novel axis regulates adipocyte plasticity
    Sean Hartig; Fiscal Year: 2013
    ..I anticipate that my studies will provide new clues into the complex regulatory networks controlling energy balance in fat cells. If my hypothesis is true, the Ubc9/miR-30a axis might be exploited in novel therapies to manage T2DM. ..
  16. Rev-ERBa Regulates Mitochondrial Biogenesis, Adiposity, and Insulin Action
    Thomas H Reynolds; Fiscal Year: 2010
    ..The overall goal of this proposal is to learn more about how Rev-ERBa reduces adiposity and enhances insulin action. ..
  17. Pathogenic Mechanisms of Fatty Liver Disease
    Mohammad S Siddiqui; Fiscal Year: 2011
    ....
  18. Effects of Dietary Fat on Contractile and Mitochondrial Function in Heart Failure
    Margaret P Chandler; Fiscal Year: 2010
    ..fat diet may include activation of peroxisome proliferator activated receptors (PPAR) and their co-activator PPAR gamma co-activator-1 (PGC-1) that operate to stimulate cardiac gene expression of the FA metabolic pathways and ..
  19. Connection of Mineral and Energy Metabolism by the Nuclear Receptor PPAR-gamma
    Yihong Wan; Fiscal Year: 2013
    ..Therefore, this investigation will significantly impact the broader scientific, clinical, and patient community. ..
  20. Sleep Apnea and Dysregulation of Lipid Metabolism
    Vsevolod Y Polotsky; Fiscal Year: 2013
    ..abstract_text> ..
  21. Virtual Screening Development to Complement Experimental Screening for PPAR Modul
    Stephanie N Lewis; Fiscal Year: 2012
    ....
  22. Modulation of PPAR-gamma phosphorylation at S273 regulates insulin sensitivity
    ALEXANDER BANKS; Fiscal Year: 2013
    ....
  23. Role of PPAR-gamma in Smoking-induced COPD Progression and Steroid Resistance
    Raju C Reddy; Fiscal Year: 2013
    ..It would also establish the feasibility of an innovative approach to restoring therapeutic glucocorticoid sensitivity, thereby promoting PPAR-g-glucocorticoid synergy, in COPD and potentially in other steroid-resistant diseases. ..
  24. BISPHENOL A EFFECTS ON THE PERIPHERAL MECHANISMS OF PENILE ERECTION
    Nestor F Gonzalez-Cadavid; Fiscal Year: 2011
    ....
  25. Sex Hormones and the Innate Immune Response to Influenza Infection
    DIONNE ROBINSON; Fiscal Year: 2012
    ..These data and our preliminary studies support the need for an in depth evaluation of the effects of sex steroid hormones on immune responses during influenza A infection. ..
  26. APOLIPOPROTEIN GENES AND ATHEROGENESIS IN ANIMALS
    Nobuyo Maeda; Fiscal Year: 2012
    ..Using mouse genetics as a tool, we aim to determine how some common human genetic differences affect atherosclerosis and how the genetic effects are influenced by being overweight and by other common gene variants. ..
  27. CNS PPAR gamma and energy homeostasis
    HEIDI E KOCALIS; Fiscal Year: 2011
    ..If a role for PPARy in CNS controlled energy homeostasis is indicated, this will establish the brain as yet another target of PPARy agonist drugs. ..
  28. 5-HT Stimulation of Mitochondrial Biogenesis and Acute Kidney Injury
    Rick G Schnellmann; Fiscal Year: 2013
    ..Ultimately, these studies may lead to new therapeutic approaches to increase cell and organ survival and function in numerous pathologic conditions. ..
  29. Vascular Mechanisms in Homocysteinemia and Atherosclerosis
    Steven R Lentz; Fiscal Year: 2012
    ..The goals of this project are to define the molecular mechanisms by which hyperhomocysteinemia and hypercholesterolemia, alone or in combination, lead to adverse vascular events, and to identify new targets for therapy. ..
  30. PPAR-gamma-mediated neuroprotection against HIV-1 and alcohol CNS injury
    Yuri Persidsky; Fiscal Year: 2009
    ..The availability of PPARgamma agonists approved for clinical use will permit rapid translation of experimental findings into therapeutic applications. ..
  31. PPAR gamma regulates vascular endothelial reactive species production in diabetes
    C Michael Hart; Fiscal Year: 2012
    ..abstract_text> ..
  32. Effects of fish oil on inflammation and metabolic syndrome
    Philip A Kern; Fiscal Year: 2012
    ..Before and after treatment with fish oils, insulin sensitivity will be measured, along with intramyocellular lipid and genes or proteins involved in insulin action and muscle lipid oxidation ..
  33. PPAR-Gamma's Role in Aberrant Adipogenesis and Fibrosis in Systemic Sclerosis
    BENJAMIN DOUGLAS KORMAN; Fiscal Year: 2013
    ..This work will help me to develop the knowledge and skills necessary to become an independent investigator and ultimately a future leader in rheumatology and the field of SSc research. ..
  34. PPAR gamma and Nox4 in pulmonary hypertension
    Roy L Sutliff; Fiscal Year: 2013
    ..The long-term goals of this proposal are to define mechanisms by which PPARg activation attenuates PH and to facilitate the development of new PH therapy. ..
  35. Dysregulated Pathways in Pulmonary Fibrosis
    Keith C Olsen; Fiscal Year: 2012
    ..This application seeks to improve the understanding of the disease and to identify possible therapeutic targets. ..
  36. Stimulation of Mitochondrial Biogenesis with PDE3 Inhibitors
    Ryan M Whitaker; Fiscal Year: 2013
    ..As mitochondrial biogenesis is a ubiquitous process, these agents may prove effective in the treatment of acute injury in other organs including heart, liver and brain. ..
  37. Effects of ethanol on lipid metabolism
    Min You; Fiscal Year: 2013
    ....
  38. Mechanisms of Brd2 immunoprotection from insulin resistance
    Gerald V Denis; Fiscal Year: 2011
    ..abstract_text> ..
  39. Metabolic syndrome and hippocampal Ca2+ dysregulation in aging memory decline
    Olivier Thibault; Fiscal Year: 2013
    ..Therefore, even if the central hypothesis is rejected, the studies proposed will provide more definitive evidence for the impact o metabolic syndrome, as well as the actions of TZDs, on the brain. ..
  40. The role of smooth muscle PPAR gamma in neointima formation
    SETH BERNAT FURGESON; Fiscal Year: 2013
    ..In Aim Three, we will determine which agent can reduce neointima size the greatest after wire injury. ..
  41. Microparticles as Messengers of Communication Between Blood and Vascular Cells
    Richard P Phipps; Fiscal Year: 2010
    ..Understanding this new way of cell to cell communication will lead to new methods and biomarkers to detect disease and to new ways of delivering therapy to reduce the consequences of diabetes and other diseases. ..
  42. Pathophysiology of PPARgamma in the lung
    Hong Du; Fiscal Year: 2012
    ..These studies will provide new approaches to design strategies and discover drugs to combat emphysema and COPD. ..
  43. Peroxisome Proliferator-Activated Receptor (gamma) in Lung Cancer
    Raphael A Nemenoff; Fiscal Year: 2013
    ....
  44. Mechanisms of PPAR-gamma Enhancement of Cognitive Function in Alzheimer's Disease
    Kelly T Dineley; Fiscal Year: 2013
    ..These findings will have significant impact on our understanding of, and treatment options for, Alzheimer's disease. ..
  45. PPAR-gamma Signaling in Normal Pilosebaceous Units and in Scarring Alopecia
    Pratima Karnik; Fiscal Year: 2013
    ..PHS 398/2590 (Rev. 11/07) Page Continuation Format Page ..
  46. PPARy and Uterine Vascular Dysfunction in Diabetic Pregnancy
    Natalia I Gokina; Fiscal Year: 2011
    ....
  47. PPAR-gamma and Vascular Lesion Formation
    Yuqing Eugene Chen; Fiscal Year: 2013
    ....
  48. MicroRNAs regulate proliferative signaling pathways in pulmonary hypertension
    DAVID EMERSON GREEN; Fiscal Year: 2013
    ....
  49. Chronic DTH and IFN-gamma in Human Graft Arteriosclerosis
    Jordan S Pober; Fiscal Year: 2010
    ....
  50. Peptidergic Control of Appetitive Ingestive Behaviors
    TIMOTHY JON BARTNESS; Fiscal Year: 2013
    ..This will greatly impact behavioral or drug therapies for obesity and for the genetic disorder Prader-Willi-Syndrome characterized by obesity and uncontrollable FH. ..
  51. Diabetic Cardiomyopathy and the Alpha Arrestin Proteins
    Richard T Lee; Fiscal Year: 2013
    ..Furthermore, we will have new insight on the roles of Alpha Arrestin proteins in the myocardium. ..
  52. Development of Novel Class of Anti-Inflammatory Drugs
    KEN CARTER; Fiscal Year: 2013
    ..analogs of 61610, (2) perform compound screening based on LANCL2 binding, cAMP/PKA signaling and exclusion of PPAR gamma activation to select 3 lead derivatives/analogs for further development in vivo, and (3) compare the oral ..
  53. Anti-angiogenic Barriers to Tumor Development
    Susan E Crawford; Fiscal Year: 2010
    ..Moreover, a significant decrease in PEDF mRNA was evident when PPAR gamma was over-expressed in rodent livers and PEDF interacted with nuclear receptors suggesting that PEDF may be a new ..
  54. Metabolic regulation of stem cell behavior and longevity
    David W Walker; Fiscal Year: 2013
    ....
  55. Th1 and Th17 Mediators in Experimental Emphysema
    Farrah Kheradmand; Fiscal Year: 2013
    ..This application captures some of the critical initiation events in smoke-induced inflammation and applies this knowledge to explore new therapeutic options in emphysema. ..
  56. Nuclear receptor mechanisms controlling macrophage function in health and disease
    Ajay Chawla; Fiscal Year: 2013
    ..molecular, cellular, and genetic approaches, including tissue-specific knockouts, to further investigate how PPAR gamma and delta orchestrate macrophage gene expression during injury and repair...
  57. Transcriptional Control of Macrophage in Atherogenesis
    Ajay Chawla; Fiscal Year: 2013
    ..dependent on the transcriptional activity of Peroxisome Proliferator Activated Receptors gamma and delta (PPAR gamma and delta), providing a mechanistic basis for the protective functions of these receptors in obesity-induced ..
  58. PPAR gamma in pediatric sepsis and the inflammatory response in obesity
    JENNIFER MELISSA KAPLAN; Fiscal Year: 2013
    ..The proposed research is significant because it can lead to novel therapies for patients with sepsis, including the potential use of FDA-approved PPARg ligands, thiazolidinediones, which can augment the PPARg pathway. ..
  59. Effect of PPAR?? Ligands on Alcohol-Induced Alveolar Macrophage Dysfunction
    Samantha M Yeligar; Fiscal Year: 2011
    ....
  60. PPAR gamma as a therapeutic target in COPD
    Thomas J Mariani; Fiscal Year: 2013
    ....
  61. Mechanisms Regulating Reversal of Malignancy
    Priscilla Furth; Fiscal Year: 2009
    ..2. c. Test if pharmacological RXRalpha and/or PPARgamma agonists alone or in combination prevent development of ERalpha ductal hyperplasia and DCIS. ..
  62. Regulation of Prostate Cancer Growth by PPARg Ligands
    LAMONICA VANETTE STEWART; Fiscal Year: 2010
    ..This information can then be used to design prostate cancer treatments involving PPARg ligands that can be tested initially in animal models and then further explored in clinical trials. ..
  63. Linking partial and non-agonist induced dynamics to PPAR gamma functions
    TRAVIS SHANE HUGHES; Fiscal Year: 2013
    ..g. heart failure) from wanted effects (i.e. anti-diabetic efficacy, anti-inflammation). This will improve diabetes treatment and open up possibilities for PPAR targeted therapies for atherosclerosis and autoimmune disorders. ..
  64. Echium Oil Modulates Macrophage Inflammation by Promoting Alternative Activation
    AMANDA WIBLEY; Fiscal Year: 2010
    ..The nuclear hormone receptor PPAR gamma acts as a lipid-sensor and likely directs this modulation of macrophage activation phenotypes by omega-3 fatty ..
  65. ROLE OF PPAR GAMMA IN LUPUS NEPHRITIS
    Gary Gilkeson; Fiscal Year: 2005
    ..Activators of the nuclear receptor PPAR gamma inhibit macrophage and mesangial cell activation...
  66. MOLECULAR BASIS OF HIV LIPODYSTROPHY: ROLE OF VPR
    Ashok Balasubramanyam; Fiscal Year: 2003
    ....
  67. Matrix Metalloproteinases and PPAR Gamma in Sarcoidosis
    Daniel Culver; Fiscal Year: 2009
    ..abstract_text> ..
  68. Tumor Suppression Through Oxidized Glycerophosphocholines
    Raymond L Konger; Fiscal Year: 2010
    ..The proposed studies will determine whether tumor promoters induce ox-GPCs that serve a protective function in neoplastic development by activating growth-inhibitory PAF-R and/or PPAR?. ..
  69. CLASS B SCAVENGER RECEPTORS AND FOAM CELL FORMATION
    DENEYS VAN DER WESTHUYZEN; Fiscal Year: 2003
    ..The extent of atherosclerosis will be quantified by lesion size and cholesterol/cholesterol ester content. ..
  70. Association of PPAR gamma ligands & colonic neoplasia
    James Lewis; Fiscal Year: 2006
    ..Our results will allow us to translate the existing in vitro and in vivo observations to the intact human colon and could lead to further chemoprevention strategies. ..
  71. PPAR- GAMMA LIGANDS IN ULCERATIVE COLITIS
    James Lewis; Fiscal Year: 2001
    ..It is expected that in the final 6 months of this project, the investigators will organize a multicenter randomized controlled trial of troglitazone in the treatment of mild to moderate ulcerative colitis. ..
  72. Role of PPAR-gamma Isoforms in Regulation of Macrophage apoE & LPL Expression
    Jheem Medh; Fiscal Year: 2006
    ..Information about ligand specificities of individual PPAR-g protein isoforms and their specific gene targets will allow for the selective induction of desirable genes and repression of harmful ones. [unreadable] [unreadable] [unreadable]..
  73. Chemoprevention of Pituitary Corticotroph Tumors
    Anthony Heaney; Fiscal Year: 2006
    ..Our ultimate goal is to develop a rationale for clinical application of these PPAR-gamma ligands as a novel medical therapy in Cushing's disease. ..
  74. Normal and Type-2 Diabetic Platelet Proteomics and Storage for Transfusion
    Richard Phipps; Fiscal Year: 2007
    ..Overall, our findings will form the foundation for clinical studies to evaluate new biomarkers of platelet function and improve the platelet deterioration that occurs during the storage period prior to transfusion. (End of Abstract) ..
  75. PPAR GAMMA AGONISTS FOR THE PREVENTION OF COLON CANCER
    Michael Wargovich; Fiscal Year: 2002
    ..The overall investigating agonists of PPAR gamma as possible chemopreventives for colon cancer. Colon cancer is the second cancer...
  76. The impact of PPAR-gamma and estrogen receptor crosstalk on insulin action
    Andrea Hevener; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..